Literature DB >> 10340405

Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.

S Biethahn1, F Alves, S Wilde, W Hiddemann, K Spiekermann.   

Abstract

Acute myelogenous leukemia (AML) is characterized by the malignant transformation of hematopoietic stem cells leading to dysregulated growth and differentiation of myeloid cells. Normally, proliferation and differentiation of myeloid cells are regulated by cytokines such as granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). Abnormal signaling of the signal transduction pathway from the cytokine receptors via Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) might be involved in the pathogenesis of AML. We examined whether an abnormal expression of one of the four JAKs, STAT1, STAT3, STAT5, or the tyrosine phosphatase SHP-1, a negative regulator of this pathway, is associated with malignant transformation in AML. Analysis of the expression of proteins of the JAK/STAT pathway in normal myeloid cells at three stages of maturation revealed a strong expression of all proteins in CD34+ cells, whereas the level of the proteins was significantly lower in granulocytic precursors and mature neutrophils. Furthermore, during maturation the relation of the isoforms of STAT1 and STAT3 changed from predominantly alpha to predominantly beta. Leukemic blast cells from 25 patients and 12 cell lines showed a high level of STAT proteins and SHP-1, whereas a deficiency of at least one of the four JAKs was found in 10 of 25 patients. In primary AML blast cells a deficiency of three JAKs was more common in patients with an abnormal karyotype. In addition, a lack of JAK2 and Tyk2 protein was strongly associated with the FAB M2 phenotype. The proliferation rate in response to GM-CSF available in a small number of patients appears to be related to the JAK2 expression. Our data suggest that the degree of expression of G-CSF/GM-CSF receptor-associated proteins of the JAK/STAT pathway in normal myeloid cells is related with their clonogenic potential. STAT3 appears to be involved in early differentiation. Similar to CD34+ cells, it is likely that the high levels of STATs and SHP-1 found in leukemic cells reflects their proliferative activity, whereas a lack of members of the JAK family might lead to an inability to proliferate in response to G-CSF/GM-CSF described in a considerable percentage of AML blasts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340405     DOI: 10.1016/s0301-472x(99)00017-x

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

Review 1.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

2.  Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Authors:  James Marvin; Suchitra Swaminathan; Geoffrey Kraker; Amy Chadburn; James Jacobberger; Charles Goolsby
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

3.  Signal transduction activator of transcription 5 (STAT5) dysfunction in autoimmune monocytes and macrophages.

Authors:  S A Litherland; T X Xie; K M Grebe; A Davoodi-Semiromi; J Elf; N S Belkin; L L Moldawer; M J Clare-Salzler
Journal:  J Autoimmun       Date:  2005-03-23       Impact factor: 7.094

4.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  George S Laszlo; Rhonda E Ries; Chelsea J Gudgeon; Kimberly H Harrington; Todd A Alonzo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2014-03-24

5.  Differential expression and potential role of SOCS1 and SOCS3 in Wallerian degeneration in injured peripheral nerve.

Authors:  Elizabeth I Girolami; Delphine Bouhy; Michael Haber; Howard Johnson; Samuel David
Journal:  Exp Neurol       Date:  2009-07-02       Impact factor: 5.330

6.  Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome.

Authors:  Blaine W Robinson; Nai-Kong V Cheung; Christos P Kolaris; Suresh C Jhanwar; John K Choi; Neil Osheroff; Carolyn A Felix
Journal:  Blood       Date:  2008-01-14       Impact factor: 22.113

7.  Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; T Kris Eckols; Mikhail Kolosov; Paul Lang; Kurt Christensen; Dean P Edwards; David J Tweardy
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

8.  Filamins but not Janus kinases are substrates of the ASB2α cullin-ring E3 ubiquitin ligase in hematopoietic cells.

Authors:  Isabelle Lamsoul; Monique Erard; Peter F M van der Ven; Pierre G Lutz
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

9.  Selective STAT3-α or -β expression reveals spliceform-specific phosphorylation kinetics, nuclear retention and distinct gene expression outcomes.

Authors:  Ivan H W Ng; Dominic C H Ng; David A Jans; Marie A Bogoyevitch
Journal:  Biochem J       Date:  2012-10-01       Impact factor: 3.857

10.  STAT3 in Cancer-Friend or Foe?

Authors:  Hai-Feng Zhang; Raymond Lai
Journal:  Cancers (Basel)       Date:  2014-07-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.